Tissium, a Paris, France- and Boston, MA-based medtech company developing biomorphic programmable polymers for tissue reconstruction, raised €50M in Series C financing.
The round was led by Cathay Health, affiliated to global investment firm Cathay Capital, with participation from existing shareholders Sofinnova Partners, and others. As part of the financing, Cathay Health Co-founder and Managing Partner Hongjie Hu will be joining Tissium’s board of directors.
The company intends to use the funds to continue to execute on its development plan, up to the commercialization of its nerve repair, hernia repair and cardiovascular sealant products.
Led by Christophe Bancel, CEO, Tissium is a medtech company that is dedicated to the development and commercialization of a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, Currently, the company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular, which are designed to enhance the tissue reconstruction process. The company also develops delivery and activation devices for enhanced performance and usability of its products.
Tissium’s technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who cofounded the company in 2013.